Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Biodesix, Inc. develops and commercializes blood-based diagnostic tests focused on lung disease, including lung cancer diagnosis, treatment guidance, and monitoring. Its core products combine proteomics, genomics, and AI technologies to provide personalized, timely clinical insights for healthcare providers and biopharmaceutical partners. Biodesix operates CLIA-certified labs in the U.S., serving pulmonologists, hospitals, and research institutions with proprietary tests that improve patient outcomes and reduce unnecessary procedures.
This description was generated via AI from an annual report. Updated about 1 year ago.